Drug Type Small molecule drug |
Synonyms Fenformin, Phenformin, β-Phenethybiguanide + [3] |
Target |
Mechanism PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC10H16ClN5 |
InChIKeyYSUCWSWKRIOILX-UHFFFAOYSA-N |
CAS Registry834-28-6 |
Start Date01 Sep 2021 |
Sponsor / Collaborator- |
Start Date18 Dec 2019 |
Sponsor / Collaborator |
Start Date01 Jan 2017 |
Sponsor / Collaborator |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08352 | Phenformin Hydrochloride |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | KR | 18 Dec 2019 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1 | 18 | xmncyfekcs(zwxodnkxsu) = Two patients were hospitalized due to lactic acidosis. lbgpfsospk (wgfmyfgcop ) View more | Positive | 31 May 2023 |